公开(公告)号：US20240197703A1

公开(公告)日：2024-06-20

申请号：US18144737

申请日：2023-05-08

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

CPC classification number: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20150141402A1

公开(公告)日：2015-05-21

申请号：US14548749

申请日：2014-11-20

Applicant: PFIZER INC.

Inventor： Douglas Carl Behenna ,  Hengmiao Cheng ,  Sujin Cho-Schultz ,  Theodore Otto Johnson, JR. ,  John Charles Kath ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Simon Paul Planken

IPC: C07D473/16

CPC classification number: C07D473/16 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5386 ,  C07D473/18 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中Q，G，环A，环B，R1，R2，R3，R4，R5，R5a，R6，R7，R8，R9， R 11，R 12，R 13，R 14，R 15，R 16，R 17，R 18，R 19，R 20，R 21，R 22，R 23，R 24和m如本文所定义。 新型嘌呤衍生物可用于治疗哺乳动物中异常细胞生长，如癌症。 另外的实施方案涉及含有化合物的药物组合物和使用化合物和组合物治疗哺乳动物异常细胞生长的方法。

公开(公告)号：US09290496B2

公开(公告)日：2016-03-22

申请号：US14548749

申请日：2014-11-20

Applicant: PFIZER INC.

Inventor： Douglas Carl Behenna ,  Hengmiao Cheng ,  Sujin Cho-Schultz ,  Theodore Otto Johnson, Jr. ,  John Charles Kath ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Simon Paul Planken

IPC: A61K31/519 ,  C07D473/18 ,  A61P35/00 ,  A61K31/5377 ,  C07D498/10 ,  A61K31/5386 ,  C07D487/04 ,  A61K31/52 ,  C07D473/16 ,  C07D519/00

CPC classification number: C07D473/16 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/5386 ,  C07D473/18 ,  C07D519/00

Abstract: The present invention relates to compounds of formula (I) or pharmaceutically acceptable salts thereof, wherein Q, G, ring A, ring B, R1, R2, R3, R4, R5, R5a, R6, R7, R8, R9, R10, R11, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, R23, R24, and m are defined herein. The novel purine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. Additional embodiments relate to pharmaceutical compositions containing the compounds and to methods of using the compounds and compositions in the treatment of abnormal cell growth in mammals.

Abstract translation: 本发明涉及式（I）化合物或其药学上可接受的盐，其中Q，G，环A，环B，R1，R2，R3，R4，R5，R5a，R6，R7，R8，R9， R 11，R 12，R 13，R 14，R 15，R 16，R 17，R 18，R 19，R 20，R 21，R 22，R 23，R 24和m如本文所定义。 新型嘌呤衍生物可用于治疗哺乳动物中异常细胞生长，如癌症。 另外的实施方案涉及含有化合物的药物组合物和使用化合物和组合物治疗哺乳动物异常细胞生长的方法。

公开(公告)号：US20220401424A1

公开(公告)日：2022-12-22

申请号：US17246551

申请日：2021-04-30

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: A61K31/444 ,  A61K45/06 ,  C07D519/00 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula I and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US20220089580A1

公开(公告)日：2022-03-24

申请号：US17544303

申请日：2021-12-07

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US11684616B2

公开(公告)日：2023-06-27

申请号：US17246551

申请日：2021-04-30

Applicant: PFIZER INC.

Inventor： Joyann Barber ,  Sujin Cho-Schultz ,  Matthew L. Del Bel ,  Rebecca Anne Gallego ,  Mingying He ,  Mehran Jalaie ,  Robert Steven Kania ,  Michele Ann McTigue ,  Sajiv Krishnan Nair ,  Anne-Marie Dechert Schmitt ,  Jamison Bryce Tuttle ,  Dahui Zhou ,  Ru Zhou

IPC: C07D471/04 ,  C07D519/00 ,  A61K31/444 ,  A61K45/06

CPC classification number: A61K31/444 ,  A61K45/06 ,  C07D471/04 ,  C07D519/00

Abstract: This invention relates to compounds of general Formula I






and pharmaceutically acceptable salts thereof, in which R1, R2, R3a, R3b, and R4 are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11220494B2

公开(公告)日：2022-01-11

申请号：US16942209

申请日：2020-07-29

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US10766884B2

公开(公告)日：2020-09-08

申请号：US16391836

申请日：2019-04-23

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US20190330196A1

公开(公告)日：2019-10-31

申请号：US16391836

申请日：2019-04-23

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.